ID

22146

Beschrijving

EMD 521873 in Advanced Solid Tumors, MTD Finding; ODM derived from: https://clinicaltrials.gov/show/NCT01032681

Link

https://clinicaltrials.gov/show/NCT01032681

Trefwoorden

Versies (1)
  1. 21-05-17 21-05-17 -
Geüploaded op

21 mei 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Non-Hodgkin Lymphoma NCT01032681

Engels

Eligibility Non-Hodgkin Lymphoma NCT01032681

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. signed written informed consent
Beschrijving

informed consent

Datatype

boolean

Alias
UMLS CUI [1]
C0021430
2. male or female, aged ≥ 18 years, inpatient for treatment phase of cycle 1 and 2, outpatient treatment possible for subsequent cycles
Beschrijving

gender, age, treatment cycle

Datatype

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
UMLS CUI [3]
C1302181
3. histologically or cytologically proven metastatic or locally advanced solid tumors (epithelial or mesenchymal cancers) or b-cell non-hodgkin lymphoma for which no standard therapy exists or after failure of standard therapy
Beschrijving

metastatic or locally advanced tumor, b-cell non-hogdkin lymphoma

Datatype

boolean

Alias
UMLS CUI [1]
C2939420
UMLS CUI [2]
C0677984
UMLS CUI [3,1]
C0079731
UMLS CUI [3,2]
C0024305
4. eastern cooperative oncology group (ecog) performance status of 0 to 1 at study entry and an estimated life expectancy of at least 3 months
Beschrijving

ecog, life expectancy

Datatype

boolean

Alias
UMLS CUI [1]
C1520224
UMLS CUI [2]
C0023671
5. adequate hematological function defined by wbc count ≥ 3 x 109/l with absolute neutrophil count (anc) ≥ 1.5 x 109/l and lymphocyte count ≥ 0.5 x 109/l; platelet count ≥100 x 109/l; hemoglobin ≥9 g/dl ( if the laboratory values for hemoglobin are outside the required entry level at screening, a patient may receive a transfusion of rbc. a stable hemoglobin level of ≥9 mg/dl for at least 7 days must be achieved prior to receiving the first dose of study medication.)
Beschrijving

hematologic function, wbc, anc, lymphocyte count, platelet count, hemoglobin

Datatype

boolean

Alias
UMLS CUI [1,1]
C0221130
UMLS CUI [1,2]
C0023508
UMLS CUI [1,3]
C0948762C0200635
UMLS CUI [1,4]
C0005821
UMLS CUI [1,5]
C0019046
6. adequate hepatic function defined by a total bilirubin level ≤ 1.5 times the upper limit of normal (uln) and aspartate-aminotransferase (ast) and alanine-aminotransferase (alt) levels ≤ 2.5 x uln or, for patients with documented metastatic disease to the liver, ast and alt levels ≤ 5 x uln
Beschrijving

hepatic function

Datatype

boolean

Alias
UMLS CUI [1,1]
C0232741
UMLS CUI [1,2]
C1278039
UMLS CUI [1,3]
C0201836
UMLS CUI [1,4]
C0201899
7. no history of acute or chronic kidney disease and adequate renal function defined by an estimated creatinine clearance above 50 ml/min determined by 24-hour urine sampling or by the cockcroft-gault formula
Beschrijving

kidney function

Datatype

boolean

Alias
UMLS CUI [1,1]
C0232804
UMLS CUI [1,2]
C0812399
8. effective contraception for both male and female subjects if the risk of conception exists
Beschrijving

effective contraception

Datatype

boolean

Alias
UMLS CUI [1]
C0700589
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. prior il-2 therapy within the last 6 months
Beschrijving

il-2 therapy

Datatype

boolean

Alias
UMLS CUI [1]
C0199975
2. requirement for concurrent anticancer treatment (chemotherapy, radiotherapy, immune therapy, cytokine therapy except erythropoietin) or for concurrent systemic therapy with steroids or other immunosuppressive agents. short-term administration of steroids (i.e. for allergic reactions) is allowed.
Beschrijving

cancer treatment, immunosuppression

Datatype

boolean

Alias
UMLS CUI [1]
C0920425
UMLS CUI [2]
C0021079
3. radiotherapy, chemotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before the start of treatment in this study
Beschrijving

radiotherapy, chemotherapy, surgery, investigational drug

Datatype

boolean

Alias
UMLS CUI [1]
C1522449
UMLS CUI [2]
C0392920
UMLS CUI [3]
C0543467
UMLS CUI [4]
C0013230
4. acquired immune defects such as human immunodeficiency virus (hiv)
Beschrijving

immunodeficiency

Datatype

boolean

Alias
UMLS CUI [1]
C0021051
5. systemic autoimmune disease (e.g. lupus erythematodes, rheumatoid arthritis, addison's disease, autoimmune disease associated with lymphoma)
Beschrijving

autoimmune disease

Datatype

boolean

Alias
UMLS CUI [1]
C0004364
6. organ transplant recipients
Beschrijving

organ transplant recipient

Datatype

boolean

Alias
UMLS CUI [1]
C0376387
7. history of or active inflammatory bowel disease (e.g. crohn's disease, ulcerative colitis)
Beschrijving

inflammatory bowel disease

Datatype

boolean

Alias
UMLS CUI [1]
C0021390
8. chronic viral infections (e.g. hepatitis b virus [hbv], hepatitis c virus [hcv])
Beschrijving

chronic viral infections

Datatype

boolean

Alias
UMLS CUI [1,1]
C0042769
UMLS CUI [1,2]
C0205191
9. uncontrolled hypertension (systolic >180 mmhg, diastolic >100 mmhg)
Beschrijving

uncontrolled hypertension

Datatype

boolean

Alias
UMLS CUI [1]
C1868885
10. known hypersensitivity reactions to any of the compounds of the study medication
Beschrijving

drug hypersensitivity

Datatype

boolean

Alias
UMLS CUI [1]
C0013182
11. confirmed or clinically suspected brain metastases
Beschrijving

brain metastases

Datatype

boolean

Alias
UMLS CUI [1]
C0220650
12. pregnancy (absence to be confirmed by beta-human chorionic gonadotropin [β-hcg] test) or lactation period
Beschrijving

pregnancy, breast feeding

Datatype

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
13. clinically significant (i.e. active) cardiovascular disease: cerebral vascular accident /stroke (< 6 months prior to enrolment), myocardial infarction (< 6 months prior to enrolment), unstable angina, congestive heart failure or serious cardiac arrhythmia requiring medication.
Beschrijving

cardiovascular disease

Datatype

boolean

Alias
UMLS CUI [1]
C0007222
14. pulmonary disease which, in the opinion of the investigator, might impair the patient's respiratory tolerance to moderate pulmonary fluid overload (e.g. interstitial lung disease, severe chronic obstructive pulmonary disease)
Beschrijving

pulmonary disease

Datatype

boolean

Alias
UMLS CUI [1]
C0024115
15. all conditions which are associated with significant necroses of non tumor-bearing tissues like e.g. esophageal or gastroduodenal ulcers (< 6 months prior to enrolment), organ infarctions (< 6 months prior to enrolment) or active ischemic bowel disease
Beschrijving

necroses

Datatype

boolean

Alias
UMLS CUI [1]
C0027540
16. presence of medically significant third space fluid (pericardial effusion or ascites/ pleural infusion requiring repetitive paracentesis)
Beschrijving

third space fluid

Datatype

boolean

Alias
UMLS CUI [1]
C0031039
UMLS CUI [2]
C0003962
UMLS CUI [3]
C0032227
17. known alcohol or drug abuse
Beschrijving

alcohol or drug abuse

Datatype

boolean

Alias
UMLS CUI [1]
C0038586
18. participation in another clinical trial within the past 30 days before start of study treatment
Beschrijving

study participation

Datatype

boolean

Alias
UMLS CUI [1]
C2348568
19. all other significant diseases which, in the opinion of the investigator, might impair the patient's tolerance of study treatment.
Beschrijving

comorbidities

Datatype

boolean

Alias
UMLS CUI [1]
C0009488
20. dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
Beschrijving

mental disorder

Datatype

boolean

Alias
UMLS CUI [1]
C0004936
Terug naar het begin van de pagina

Similar models

Eligibility Non-Hodgkin Lymphoma NCT01032681

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
informed consent
Item
1. signed written informed consent
boolean
C0021430 (UMLS CUI [1])
gender, age, treatment cycle
Item
2. male or female, aged ≥ 18 years, inpatient for treatment phase of cycle 1 and 2, outpatient treatment possible for subsequent cycles
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C1302181 (UMLS CUI [3])
metastatic or locally advanced tumor, b-cell non-hogdkin lymphoma
Item
3. histologically or cytologically proven metastatic or locally advanced solid tumors (epithelial or mesenchymal cancers) or b-cell non-hodgkin lymphoma for which no standard therapy exists or after failure of standard therapy
boolean
C2939420 (UMLS CUI [1])
C0677984 (UMLS CUI [2])
C0079731 (UMLS CUI [3,1])
C0024305 (UMLS CUI [3,2])
ecog, life expectancy
Item
4. eastern cooperative oncology group (ecog) performance status of 0 to 1 at study entry and an estimated life expectancy of at least 3 months
boolean
C1520224 (UMLS CUI [1])
C0023671 (UMLS CUI [2])
hematologic function, wbc, anc, lymphocyte count, platelet count, hemoglobin
Item
5. adequate hematological function defined by wbc count ≥ 3 x 109/l with absolute neutrophil count (anc) ≥ 1.5 x 109/l and lymphocyte count ≥ 0.5 x 109/l; platelet count ≥100 x 109/l; hemoglobin ≥9 g/dl ( if the laboratory values for hemoglobin are outside the required entry level at screening, a patient may receive a transfusion of rbc. a stable hemoglobin level of ≥9 mg/dl for at least 7 days must be achieved prior to receiving the first dose of study medication.)
boolean
C0221130 (UMLS CUI [1,1])
C0023508 (UMLS CUI [1,2])
C0948762C0200635 (UMLS CUI [1,3])
C0005821 (UMLS CUI [1,4])
C0019046 (UMLS CUI [1,5])
hepatic function
Item
6. adequate hepatic function defined by a total bilirubin level ≤ 1.5 times the upper limit of normal (uln) and aspartate-aminotransferase (ast) and alanine-aminotransferase (alt) levels ≤ 2.5 x uln or, for patients with documented metastatic disease to the liver, ast and alt levels ≤ 5 x uln
boolean
C0232741 (UMLS CUI [1,1])
C1278039 (UMLS CUI [1,2])
C0201836 (UMLS CUI [1,3])
C0201899 (UMLS CUI [1,4])
kidney function
Item
7. no history of acute or chronic kidney disease and adequate renal function defined by an estimated creatinine clearance above 50 ml/min determined by 24-hour urine sampling or by the cockcroft-gault formula
boolean
C0232804 (UMLS CUI [1,1])
C0812399 (UMLS CUI [1,2])
effective contraception
Item
8. effective contraception for both male and female subjects if the risk of conception exists
boolean
C0700589 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
il-2 therapy
Item
1. prior il-2 therapy within the last 6 months
boolean
C0199975 (UMLS CUI [1])
cancer treatment, immunosuppression
Item
2. requirement for concurrent anticancer treatment (chemotherapy, radiotherapy, immune therapy, cytokine therapy except erythropoietin) or for concurrent systemic therapy with steroids or other immunosuppressive agents. short-term administration of steroids (i.e. for allergic reactions) is allowed.
boolean
C0920425 (UMLS CUI [1])
C0021079 (UMLS CUI [2])
radiotherapy, chemotherapy, surgery, investigational drug
Item
3. radiotherapy, chemotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before the start of treatment in this study
boolean
C1522449 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C0543467 (UMLS CUI [3])
C0013230 (UMLS CUI [4])
immunodeficiency
Item
4. acquired immune defects such as human immunodeficiency virus (hiv)
boolean
C0021051 (UMLS CUI [1])
autoimmune disease
Item
5. systemic autoimmune disease (e.g. lupus erythematodes, rheumatoid arthritis, addison's disease, autoimmune disease associated with lymphoma)
boolean
C0004364 (UMLS CUI [1])
organ transplant recipient
Item
6. organ transplant recipients
boolean
C0376387 (UMLS CUI [1])
inflammatory bowel disease
Item
7. history of or active inflammatory bowel disease (e.g. crohn's disease, ulcerative colitis)
boolean
C0021390 (UMLS CUI [1])
chronic viral infections
Item
8. chronic viral infections (e.g. hepatitis b virus [hbv], hepatitis c virus [hcv])
boolean
C0042769 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
uncontrolled hypertension
Item
9. uncontrolled hypertension (systolic >180 mmhg, diastolic >100 mmhg)
boolean
C1868885 (UMLS CUI [1])
drug hypersensitivity
Item
10. known hypersensitivity reactions to any of the compounds of the study medication
boolean
C0013182 (UMLS CUI [1])
brain metastases
Item
11. confirmed or clinically suspected brain metastases
boolean
C0220650 (UMLS CUI [1])
pregnancy, breast feeding
Item
12. pregnancy (absence to be confirmed by beta-human chorionic gonadotropin [β-hcg] test) or lactation period
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
cardiovascular disease
Item
13. clinically significant (i.e. active) cardiovascular disease: cerebral vascular accident /stroke (< 6 months prior to enrolment), myocardial infarction (< 6 months prior to enrolment), unstable angina, congestive heart failure or serious cardiac arrhythmia requiring medication.
boolean
C0007222 (UMLS CUI [1])
pulmonary disease
Item
14. pulmonary disease which, in the opinion of the investigator, might impair the patient's respiratory tolerance to moderate pulmonary fluid overload (e.g. interstitial lung disease, severe chronic obstructive pulmonary disease)
boolean
C0024115 (UMLS CUI [1])
necroses
Item
15. all conditions which are associated with significant necroses of non tumor-bearing tissues like e.g. esophageal or gastroduodenal ulcers (< 6 months prior to enrolment), organ infarctions (< 6 months prior to enrolment) or active ischemic bowel disease
boolean
C0027540 (UMLS CUI [1])
third space fluid
Item
16. presence of medically significant third space fluid (pericardial effusion or ascites/ pleural infusion requiring repetitive paracentesis)
boolean
C0031039 (UMLS CUI [1])
C0003962 (UMLS CUI [2])
C0032227 (UMLS CUI [3])
alcohol or drug abuse
Item
17. known alcohol or drug abuse
boolean
C0038586 (UMLS CUI [1])
study participation
Item
18. participation in another clinical trial within the past 30 days before start of study treatment
boolean
C2348568 (UMLS CUI [1])
comorbidities
Item
19. all other significant diseases which, in the opinion of the investigator, might impair the patient's tolerance of study treatment.
boolean
C0009488 (UMLS CUI [1])
mental disorder
Item
20. dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
boolean
C0004936 (UMLS CUI [1])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial